Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 8:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 4,159 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: STD Clear all
Completed Phase 3 Interventional

A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides

NCT00000802
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Atovaquone, Dapsone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
43
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 19, 2026, 8:55 PM EDT
Completed Not applicable Interventional Results available

Fish Oil for HIV-Related Inflamm-aging and Immune Senescence

NCT02102724
View directory record Official record
Conditions
HIV Infection
Interventions
Fish oil that contains omega-3 fatty acids, Placebo
Dietary Supplement
Lead sponsor
Rush University Medical Center
Other
Eligibility
40 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 19, 2026, 8:55 PM EDT
Completed Phase 3 Interventional

Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy

NCT00064623
View directory record Official record
Conditions
HIV Infections, Peripheral Nervous System Diseases, Pain
Interventions
Capsaicin Dermal Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
35
States / cities
Phoenix, Arizona • Berkeley, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2008 · Synced Oct 19, 2026, 8:55 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Feasibility of HPV Self-Collection Kits for Cervical Cancer Screening

NCT07453459
View directory record Official record
Conditions
Cervical Cancer, HPV Infection
Interventions
Qualitative Interview, Virtual Visit Standard Instructions, Virtual Visit Standard Instructions + In-Person Registration Navigation
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
25 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 19, 2026, 8:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Community Influences Transitions in Youth Health (CITY) Health II - Center for the Study of Community Health

NCT04320186
View directory record Official record
Conditions
Sexually Transmitted Diseases, HIV Infections
Interventions
Entertainment education, video
Behavioral · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 25 Years
Enrollment
334 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 19, 2026, 8:55 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers

NCT02634073
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Lamivudine, Sorbitol
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 19, 2026, 8:55 PM EDT
Completed Phase 2 Interventional

A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.

NCT00000641
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Ciprofloxacin hydrochloride, Ethambutol hydrochloride, Amikacin sulfate, Azithromycin, Rifampin, Clofazimine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
16
States / cities
Torrance, California • Indianapolis, Indiana • St Louis, Missouri + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 19, 2026, 8:55 PM EDT
Completed Phase 1 Interventional

Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)

NCT00001041
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
rgp120/HIV-1MN
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 40 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 19, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP

NCT00076037
View directory record Official record
Conditions
HIV Infections
Interventions
HIV CTL MEP administered with RC529-SE adjuvant, GM-CSF
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 19, 2026, 8:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

HIV Fat Redistribution and the Evaluation of Brown Fat

NCT01098045
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 60 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Oct 19, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals

NCT00001042
View directory record Official record
Conditions
HIV Infections
Interventions
Aluminum hydroxide, Lipid A, Monophosphoryl, Lipid A, Liposome-encapsulated monophosphoryl, Syntex adjuvant formulation, MF59, Threonyl Muramyl Dipeptide, rgp120/HIV-1 SF-2, MTP-PE/MF59
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1996
U.S. locations
3
States / cities
St Louis, Missouri • Rochester, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 19, 2026, 8:55 PM EDT
Completed Phase 1 Interventional

A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma

NCT00000954
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride, Zalcitabine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 19, 2026, 8:55 PM EDT
Completed Not applicable Interventional

A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal Meningitis

NCT00002305
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Flucytosine, Fluconazole, Amphotericin B
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
44
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Candidate HIV Vaccine

NCT00089531
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVDNA016-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 44 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 19, 2026, 8:55 PM EDT
Completed Phase 1 Interventional

A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome

NCT00000737
View directory record Official record
Conditions
Cachexia, HIV Infections, HIV Wasting Syndrome
Interventions
Dronabinol, Megestrol acetate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Denver, Colorado • Chicago, Illinois • Wichita, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2008 · Synced Oct 19, 2026, 8:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of HIV Infection and Highly Active Antiretroviral Treatment (HAART) on Bone Homeostasis

NCT01020045
View directory record Official record
Conditions
HIV Infection, Osteopenia, Osteoporosis
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 19, 2026, 8:55 PM EDT
Completed No phase listed Observational

Evaluation of Cardiovascular Effects of Smoking Cessation in HIV Patients

NCT00918073
View directory record Official record
Conditions
HIV Infections, Smokers
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
16 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2013 · Synced Oct 19, 2026, 8:55 PM EDT
Completed Not applicable Interventional Results available

Digital Star: HIV Prevention for Youth in Mental Health Treatment

NCT02921841
View directory record Official record
Conditions
Human Immunodeficiency Virus, Mental Health
Interventions
D*STAR, D*HEALTH
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
13 Years to 20 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 19, 2026, 8:55 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of a Human Immunodeficiency Virus (HIV) Blood Screening Assay

NCT00686205
View directory record Official record
Conditions
Healthy Donors, HIV Positive
Interventions
collection of follow-up sample based on PRISM HIV O Plus result
Device
Lead sponsor
Abbott Diagnostics Division
Industry
Eligibility
17 Years and older
Enrollment
24,111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
7
States / cities
Davenport, Iowa • Kansas City, Missouri • Dayton, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2011 · Synced Oct 19, 2026, 8:55 PM EDT
Completed Not applicable Interventional

Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People

NCT00028366
View directory record Official record
Conditions
HIV Infections
Interventions
Fosamprenavir, Lopinavir/Ritonavir, Ritonavir, Tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 19, 2026, 8:55 PM EDT
Completed Not applicable Interventional

A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARC

NCT00002046
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
Tucson, Arizona • Chicago, Illinois • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 8:55 PM EDT
Completed Not applicable Interventional Results available

Feasibility of the Mindfulness-Based Stress Reduction Intervention for Black Women Living With HIV

NCT04193605
View directory record Official record
Conditions
HIV Infections, Health Behavior
Interventions
Mindfulness
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 19, 2026, 8:55 PM EDT
Completed Not applicable Interventional

Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection

NCT00002066
View directory record Official record
Conditions
HIV Infections
Interventions
Thymopentin
Drug
Lead sponsor
Immunobiology Research Institute
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Annandale, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Multicenter Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

NCT00000956
View directory record Official record
Conditions
HIV Infections
Interventions
gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1993
U.S. locations
2
States / cities
St Louis, Missouri • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 19, 2026, 8:55 PM EDT